151 related articles for article (PubMed ID: 31940638)
1. Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data.
Zhao Y; Wijnands JMA; Högg T; Kingwell E; Zhu F; Evans C; Fisk JD; Marrie RA; Tremlett H
Neuroepidemiology; 2020; 54(2):140-147. PubMed ID: 31940638
[TBL] [Abstract][Full Text] [Related]
2. Mining healthcare data for markers of the multiple sclerosis prodrome.
Högg T; Wijnands JMA; Kingwell E; Zhu F; Lu X; Evans C; Fisk JD; Marrie RA; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():232-240. PubMed ID: 30121490
[TBL] [Abstract][Full Text] [Related]
3. Five years before multiple sclerosis onset: Phenotyping the prodrome.
Wijnands JM; Zhu F; Kingwell E; Zhao Y; Ekuma O; Lu X; Evans C; Fisk JD; Marrie RA; Tremlett H
Mult Scler; 2019 Jul; 25(8):1092-1101. PubMed ID: 29979093
[TBL] [Abstract][Full Text] [Related]
4. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.
Wijnands JMA; Kingwell E; Zhu F; Zhao Y; Högg T; Stadnyk K; Ekuma O; Lu X; Evans C; Fisk JD; Marrie RA; Tremlett H
Lancet Neurol; 2017 Jun; 16(6):445-451. PubMed ID: 28434855
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
Chertcoff AS; Yusuf FLA; Zhu F; Evans C; Fisk JD; Zhao Y; Marrie RA; Tremlett H
Neurology; 2023 Nov; 101(20):e2026-e2034. PubMed ID: 37748884
[TBL] [Abstract][Full Text] [Related]
6. Higher health care use before a clinically isolated syndrome with or without subsequent MS.
Marrie RA; Wijnands JMA; Kingwell E; Zhu F; Zhao Y; Ekuma O; Lu X; Evans C; Fisk JD; Tremlett H
Mult Scler Relat Disord; 2019 Oct; 35():42-49. PubMed ID: 31319354
[TBL] [Abstract][Full Text] [Related]
7. Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
Yusuf F; Wijnands JM; Kingwell E; Zhu F; Evans C; Fisk JD; Zhao Y; Sutherland JM; Patrick DM; Marrie RA; Tremlett H
Mult Scler; 2021 Feb; 27(2):290-302. PubMed ID: 32250183
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal conditions in the multiple sclerosis prodrome.
Yusuf FLA; Zhu F; Evans C; Fisk JD; Zhao Y; Marrie RA; Tremlett H
Ann Clin Transl Neurol; 2024 Jan; 11(1):185-193. PubMed ID: 38115680
[TBL] [Abstract][Full Text] [Related]
9. Infection-related health care utilization among people with and without multiple sclerosis.
Wijnands JM; Kingwell E; Zhu F; Zhao Y; Fisk JD; Evans C; Marrie RA; Tremlett H
Mult Scler; 2017 Oct; 23(11):1506-1516. PubMed ID: 28273769
[TBL] [Abstract][Full Text] [Related]
10. Sex and age differences in the Multiple Sclerosis prodrome.
Yusuf FLA; Wijnands JMA; Karim ME; Kingwell E; Zhu F; Evans C; Fisk JD; Zhao Y; Marrie RA; Tremlett H
Front Neurol; 2022; 13():1017492. PubMed ID: 36408518
[TBL] [Abstract][Full Text] [Related]
11. A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada.
McKay KA; Tremlett H; Zhu F; Kastrukoff L; Marrie RA; Kingwell E
Eur J Neurol; 2016 Jun; 23(6):1093-100. PubMed ID: 26992124
[TBL] [Abstract][Full Text] [Related]
12. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
13. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
15. Prodrome in relapsing-remitting and primary progressive multiple sclerosis.
Wijnands JMA; Zhu F; Kingwell E; Zhao Y; Evans C; Fisk JD; Marrie RA; Tremlett H
Eur J Neurol; 2019 Jul; 26(7):1032-1036. PubMed ID: 30714270
[TBL] [Abstract][Full Text] [Related]
16. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
17. Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Lu E; Zhu F; Zhao Y; van der Kop M; Sadovnick AD; Synnes A; Dahlgren L; Traboulsee A; Tremlett H
Mult Scler; 2014 Aug; 20(9):1260-4. PubMed ID: 24500603
[TBL] [Abstract][Full Text] [Related]
18. Multiple cause of death analysis in multiple sclerosis: A population-based study.
Harding K; Zhu F; Alotaibi M; Duggan T; Tremlett H; Kingwell E
Neurology; 2020 Feb; 94(8):e820-e829. PubMed ID: 31932517
[TBL] [Abstract][Full Text] [Related]
19. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010).
Kingwell E; Zhu F; Marrie RA; Fisk JD; Wolfson C; Warren S; Profetto-McGrath J; Svenson LW; Jette N; Bhan V; Yu BN; Elliott L; Tremlett H
J Neurol; 2015 Oct; 262(10):2352-63. PubMed ID: 26205633
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab and prescription medication use in the MS population.
Chertcoff A; Ng HS; Zhu F; Zhao Y; Kingwell E; Tremlett H
Mult Scler Relat Disord; 2020 Jul; 42():102086. PubMed ID: 32403069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
